semaglutide plus tirzepatide TrimRX Cardiovascular outcomes of semaglutide and

Thank you Elevo Learning for sharing this quick lesson.Elevo Learning Elevo Learning 1moDon Austin shared thisHow does a seasoned Superintendent lead a group of specialized experts

Aslan 1992)

Full disclaimer 1.Retatrutide (LY3437943) is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly 2.Phase 2 trials demonstrated up to 24.2% body weight loss at 48 weeksthe highest weight loss ever reported in a Phase 2 obesity trial 3.Triple mechanism activates multiple metabolic pathways: appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy expenditure (glucagon) 4.Currently in Phase 3 TRIUMPH trials for weight management, type 2 diabetes, NASH, and osteoarthritis

Similar content being viewed by others Background Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons in the brain and spinal cord leading to paralysis and eventually death, usually within 3 to 5 years of diagnosis